Skip to content
Saturday 8 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Product/Service

  • Alpaca Launches German Equities Trading via Deutsche Börse Xetra

    July 21, 2026

    Broker partners can offer access to German equities through the Frankfurt Stock Exchange, one of the world’s largest trading venues

  • Sagepath Reply Recognized in the 2026 Gartner® Market Guide for Strategic Website Agencies

    July 21, 2026

    Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. This marks the third time Sagepath Reply has been named in the Market Guide, following its previous inclusions in 2023 and 2025. This press release features multimedia. View the full release [...]

  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    July 21, 2026

    VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy in treatment-naïve adults living with HIV Real-world OPERA data continues to strengthen the evidence base for Cabenuva, the only complete long-acting injectable HIV treatment regimen Six-month results from the CLARITY study will report participant experience and acceptability of long-acting cabotegravir versus lenacapavir injections after a single dose in HIV-negative adults

  • New Victoria Hospital Goes Live with MEDITECH Expanse to Deliver New Era of Care

    July 21, 2026

    The new cloud-based EPR empowers patients and improves clinician experience

  • CapVest Completes Acquisition of TSG

    July 21, 2026

    TSG to accelerate its growth as a leading multi-energy infrastructure services provider across Europe; management and HLD reinvesting alongside CapVest as significant minority shareholders

  • Expensify Expands Collaboration with Marqeta to Bring its Card Offering into Europe

    July 21, 2026

    NEWS HIGHLIGHTS: Building on their long-term relationship in the US, Expensify has leveraged Marqeta’s card issuing platform to bring its expense management card offering to the UK and EU. Expensify customers in Europe can now access the same spend management capabilities that have allowed for the rapid growth of its card offering in the US. Marqeta’s comprehensive platform provides the multinational card issuing capabilities that enable customers to scale their card programs with a single integration.

  • Expensify Launches Corporate Card in Europe

    July 20, 2026

    Finance teams across the UK and EU can now issue Expensify Visa® Commercial Cards for real-time spend visibility, built-in policy controls, and fewer reimbursements.

  • Planet Opens London Office, Expanding European Footprint

    July 20, 2026

    UK office will serve as a convening hub for customer events, country delegations and regional talent

  • New CultureLab Findings Show Culturally Relevant Brands Worth Nearly Three Times More

    July 20, 2026

    As CMOs get less for every media dollar they spend and as brand investment in creators grows, new research reveals what the world's most valuable brands are doing differently

  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    July 20, 2026

    The EMA application is supported by data from the paediatric clinical programme for lebrikizumab, including the pivotal Phase III ADorable-1 study and the ADorable-2 long-term extension study. Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood – with around 60% of cases appearing within the first year of life1. As atopic dermatitis often begins early in life and can have a lasting impact on patients and their families, effective disease control is increasingly recognised as an important opportunity to reduce long-term disease burden and support healthier life trajectories2.

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 111
  • Next

Trending Articles

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Starling plans to ‘come out swinging’ in diversification bid

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook